BCL6 confers KRAS-mutant non–small-cell lung cancer resistance to BET inhibitors

The bromodomain and extra-terminal domain (BET) proteins are promising therapeutic targets to treat refractory solid tumors; however, inherent resistance remains a major challenge in the clinic. Recently, the emerging role of the oncoprotein B cell lymphoma 6 (BCL6) in tumorigenesis and stress respo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Guo, Jiawei, Liu, Yanan, Lv, Jing, Zou, Bin, Chen, Zhi, Li, Kun, Feng, Juanjuan, Cai, Zhenyu, Wei, Lai, Liu, Mingyao, Pang, Xiufeng
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2021
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7773368/
https://ncbi.nlm.nih.gov/pubmed/33393503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI133090
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars